Amanote Research
Register
Sign In
OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.308
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
Y. Cheng
Q. Wang
K. Li
J. Shi
L. Wu
B. Han
G. Chen
J. He
J. Wang
H. Qin
X. Li
Publisher
Elsevier BV
Related search
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist
Cancer Research
Medicine
Oncology
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Tremelimumab for Second and Third Line Treatment in Patients With Unresectable Pleural or Peritoneal Mesothelioma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial
Neurology
Neurology
P2.01-005 a Randomized Phase II Trial of Erlotinib vs S-1 in Patients With NSCLC as Third- Or Fourth-Line Therapy (HOT1002)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P109 Combined Chemotherapy Versus Topotecan Monotherapy as Second-Line Treatment for Patients With Sensitive Relapsed SCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Anlotinib Combined With S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial
Asian Pacific Journal of Cancer Prevention
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial
British Journal of Cancer
Cancer Research
Oncology
